In a subpopulation analysis of the phase III, 12-week EMPOWUR trial of patients with overactive bladder, patients receiving vibegron aged ≥ 65 and ≥ 75 years showed significant improvement from baseline in average daily micturitions and in average daily number of urge urinary incontinence and daily urgency episodes, similar to results of the overall population.

Rates of adverse events with vibegron were generally comparable to those with placebo within each age group and to those in the overall study population.

In patients with overactive bladder aged ≥ 65 and ≥ 75 years, treatment with vibegron was generally safe and well tolerated and demonstrated a safety profile consistent with that of the overall population.